Following U.S. Stocks were among the “Top Gainers” during Friday’s trade: Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX),JDS Uniphase Corp (NASDAQ:JDSU), Synthetic Biologics Inc (NYSEMKT:SYN), Foot Locker, Inc (NYSE:FL)
Their insights are depicted underneath:
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX)’s shares picked up 4.46%, and closed at $1.17.
According to PRNewswire, Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical corporation focused on developing breakthrough treatments for human disease, updated its drug development progress and stated financial results for the three months and year ended December 31, 2014.
“We enter 2015 in a strong financial position to develop our two lead drug candidates, telotristat etiprate and sotagliflozin,” said Lonnel Coats, Lexicon’s president and chief executive officer. “This year will be key for Lexicon as we complete a pivotal Phase 3 trial of telotristat etiprate in patients with carcinoid syndrome and initiate Phase 3 trials for sotagliflozin in patients with type 1 diabetes.”
In October 2014, Lexicon accomplished a partnership contract with Ipsen Pharma SAS for the commercialization of telotristat etiprate, with a focus on carcinoid syndrome, in markets outside the United States, Canada and Japan. Under the contract, Lexicon is eligible to receive up to about $145 million in aggregate upfront and milestone payments, counting an upfront payment of $23 million. In addition, Lexicon is entitled to receive royalties on net sales of telotristat etiprate by Ipsen.
Also in the fourth quarter of 2014, Lexicon accomplished concurrent debt and equity financings that resulted in gross proceeds of $293.4 million. After fees and offering expenses, the financings resulted in net proceeds of $286.0 million and are reflected in the corporation’s financial results as of December 31, 2014. In the aggregate, the financings comprised of the issuance of about 204.9 million shares of ordinary stock, with gross proceeds of $205.9 million, and $87.5 million in aggregate principal amount of 5.25% convertible senior notes due 2021.
Lexicon is a biopharmaceutical corporation focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon’s research team.
JDS Uniphase Corp (NASDAQ:JDSU), raised 4.28%, and closed at $13.89.
According to Marketwired, JDS Uniphase Corporation (JDSU), declared that Partner Communications, a leading mobile communications service provider operating under the Orange brand in Israel, has selected JDSU’s xSIGHT Customer Experience Assurance solution to manage data-hungry services as they evolve from 2G/3G to 4G mobile broadband. JDSU’s xSIGHT uses patent-pending technology innovation to significantly improve both the cost efficiency and speed of monitoring and troubleshooting advanced mobile services.
Partner chose xSIGHT because it delivers the highest performance and smallest footprint in the industry and cost-effectively scales to manage the increasing traffic volumes and rates driven by 4G services. The xSIGHT portfolio uses an entirely open architecture that enables seamless integration of Partner’s 2G/3G systems with new 4G infrastructure to protect existing investment and accelerate evolution.
The xSIGHT solution optimizes service quality and user experience by delivering key performance indicators (KPIs) and reporting in a matter of seconds contrast with traditional solutions that can be delayed by as much as 10-15 minutes or more. This substantial improvement in real-time visibility gives Partner a noteworthy advantage in differentiating real-time premium services, like VoLTE, in a highly competitive and dynamic market.
JDSU (NASDAQ: JDSU) innovates and collaborates with customers to build and operate the highest-performing and highest-value networks in the world. Our diverse technology portfolio also fights counterfeiting and enables high-powered commercial lasers for a range of applications.
Synthetic Biologics Inc (NYSEMKT:SYN) enhanced 4.26%, and closed at $2.45.
According to PRNewswire, Synthetic Biologics Inc. (SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, declared recently that Jeffrey Riley, Chief Executive Officer, is planned to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is planned to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
Mr. Riley, in addition to Synthetic Biologics’ Senior Vice President, Clinical & Regulatory Affairs, Joe Sliman, MD, MPH, will be accessible to take part in one-on-one meetings with investors who are registered to attend the conference. In order to register, please contact your ROTH representative.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology corporation developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.
Foot Locker, Inc (NYSE:FL), rose 4.10%, and closed at $59.37, hitting new 52-week high of $59.85.
According to PRNewswire, Foot Locker, Inc. (FL), the New York-based specialty athletic retailer, stated financial results for its fourth quarter and full year ended January 31, 2015.
Fourth Quarter Results:
The Corporation stated net revenue of $146 million for the 13 weeks ended January 31, 2015. This equates to earnings of $1.01 per share, an raise of 25 percent over earnings per share of $0.81 for the 13-week period ended February 1, 2014.
Fourth quarter comparable-store sales raised 10.2 percent. Total fourth quarter sales raised 6.7 percent, to $1,911 million this year, contrast with sales of $1,791 million in 2013. Not including the effect of foreign currency fluctuations, total sales for the fourth quarter raised 10.1 percent.
During the fourth quarter, the Corporation realized a gain from the sale of a property and wrote down a trademark. On a non-GAAP basis, not including these one-time events, the Corporation earned $1.00 per share, a 22 percent raise over the comparable 13-week non-GAAP earnings per share of $0.82 in 2013.
Foot Locker, Inc., together with its auxiliaries, operates as a retailer of athletic footwear and apparel. The corporation operates in two segments, Athletic Stores and Direct-to-Customers.
